Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLiminatus Pharma, Inc. Class A Common Stock Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2025 | Q3 2025 | N/A | -$0.07 | N/A | N/A | $0 |
| 10/03/2025 | Q2 2025 | N/A | $0.00 | N/A | N/A | $0 |
| 05/30/2025 | Q1 2025 | N/A | -$2.55 | N/A | N/A | $0 |
| 12/30/2024 | Q4 2024 | N/A | -$0.12 | N/A | N/A | $0 |
| 09/29/2024 | Q3 2024 | N/A | -$0.09 | N/A | N/A | $0 |
| 06/29/2024 | Q2 2024 | N/A | -$0.07 | N/A | N/A | $0 |
| 03/31/2024 | Q1 2024 | N/A | -$0.23 | N/A | N/A | $0 |
| 12/31/2023 | Q4 2023 | N/A | -$0.07 | N/A | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | -$0.04 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Liminatus Pharma, Inc. Class A Common Stock Earnings: FAQ's
Liminatus Pharma, Inc. Class A Common Stock has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 2nd, 2026 based offlast year's report dates.
The conference call for Liminatus Pharma, Inc. Class A Common Stock's latest earnings report can be listened to online.
The conference call transcript for Liminatus Pharma, Inc. Class A Common Stock's latest earnings report can be read online.
Liminatus Pharma, Inc. Class A Common Stock (:LIMN) has a recorded net income of $-2,904,299.Liminatus Pharma, Inc. Class A Common Stock has generated $-0.4 earnings per share over the last four quarters.
Liminatus Pharma, Inc. Class A Common Stock (:LIMN) has a price-to-earnings ratio of -9.35 and price/earnings-to-growth ratio is -12.86.